The global kidney (renal) fibrosis market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of chronic kidney disease and renal fibrosis in developed countries, which is driving the demand for new treatments.
The global kidney (renal) fibrosis market has been segmented on the basis of type, application and region. On the basis of type, it has been segmented into angiotensin converting enzyme (ACE) inhibitors, pirfenidone, renin inhibitors, angiotensin II receptor blockers (ARBs), vasopeptidase inhibitors. On the basis of application it has been segmented into research center, hospital and clinic. On the basis of region it has been segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa.
- Availability of new treatment options for kidney (renal) fibrosis, such as biologics, immunosuppressants, and gene therapy.
Industry Growth Insights published a new data on “Kidney (Renal) Fibrosis Market”. The research report is titled “Kidney (Renal) Fibrosis Market research by Types (Angiotensin Converting enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors), By Applications (Research Center, Hospital, Clinic), By Players/Companies Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd, Genzyme Corporation”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney (Renal) Fibrosis Market Research Report
By Type
Angiotensin Converting enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors
By Application
Research Center, Hospital, Clinic
By Companies
Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd, Genzyme Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Fibrosis Industry Outlook.svg)
Global Kidney (Renal) Fibrosis Market Report Segments:
The global Kidney (Renal) Fibrosis market is segmented on the basis of:
Types
Angiotensin Converting enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Center, Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Pfizer
- Roche
- InterMune
- Galectin Therapeutics
- La Jolla Pharmaceutical Company
- ProMetic Life-Sciences Inc.
- BioLine Rx Ltd
- Genzyme Corporation
 Fibrosis Market Overview.svg)
Highlights of The Kidney (Renal) Fibrosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Angiotensin Converting enzyme (ACE) Inhibitors
- Pirfenidone
- Renin Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Vasopeptidase Inhibitors
- By Application:
- Research Center
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney (Renal) Fibrosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Fibrosis Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Kidney (renal) fibrosis is a condition in which the kidneys become scarred and thickened. This can lead to decreased function of the kidneys, as well as increased risk for kidney failure.
Some of the major players in the kidney (renal) fibrosis market are Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd, Genzyme Corporation.
The kidney (renal) fibrosis market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Kidney (Renal) Fibrosis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Kidney (Renal) Fibrosis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Kidney (Renal) Fibrosis Market - Supply Chain
4.5. Global Kidney (Renal) Fibrosis Market Forecast
4.5.1. Kidney (Renal) Fibrosis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Kidney (Renal) Fibrosis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Kidney (Renal) Fibrosis Market Absolute $ Opportunity
5. Global Kidney (Renal) Fibrosis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
5.3.1. Angiotensin Converting enzyme (ACE) Inhibitors
5.3.2. Pirfenidone
5.3.3. Renin Inhibitors
5.3.4. Angiotensin II Receptor Blockers (ARBs)
5.3.5. Vasopeptidase Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Kidney (Renal) Fibrosis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
6.3.1. Research Center
6.3.2. Hospital
6.3.3. Clinic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Kidney (Renal) Fibrosis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Kidney (Renal) Fibrosis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Kidney (Renal) Fibrosis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Kidney (Renal) Fibrosis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Kidney (Renal) Fibrosis Demand Share Forecast, 2019-2026
9. North America Kidney (Renal) Fibrosis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
9.4.1. Research Center
9.4.2. Hospital
9.4.3. Clinic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
9.7.1. Angiotensin Converting enzyme (ACE) Inhibitors
9.7.2. Pirfenidone
9.7.3. Renin Inhibitors
9.7.4. Angiotensin II Receptor Blockers (ARBs)
9.7.5. Vasopeptidase Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Kidney (Renal) Fibrosis Demand Share Forecast, 2019-2026
10. Latin America Kidney (Renal) Fibrosis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
10.4.1. Research Center
10.4.2. Hospital
10.4.3. Clinic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
10.7.1. Angiotensin Converting enzyme (ACE) Inhibitors
10.7.2. Pirfenidone
10.7.3. Renin Inhibitors
10.7.4. Angiotensin II Receptor Blockers (ARBs)
10.7.5. Vasopeptidase Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Kidney (Renal) Fibrosis Demand Share Forecast, 2019-2026
11. Europe Kidney (Renal) Fibrosis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Kidney (Renal) Fibrosis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
11.4.1. Research Center
11.4.2. Hospital
11.4.3. Clinic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
11.7.1. Angiotensin Converting enzyme (ACE) Inhibitors
11.7.2. Pirfenidone
11.7.3. Renin Inhibitors
11.7.4. Angiotensin II Receptor Blokers (ARBs)
11.7.5. Vasopeptidase Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Kidney (Renal) Fibrosis Demand Share, 2019-2026
12. Asia Pacific Kidney (Renal) Fibrosis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Kidney (Renal) Fibrosis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
12.4.1. Research Center
12.4.2. Hospital
12.4.3. Clinic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
12.7.1. Angiotensin Converting enzyme (ACE) Inhibitors
12.7.2. Pirfenidone
12.7.3. Renin Inhibitors
12.7.4. Angiotensin II Receptor Blockers (ARBs)
12.7.5. Vasopeptidase Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Kidney (Renal) Fibrosis Demand Share, 2019-2026
13. Middle East & Africa Kidney (Renal) Fibrosis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Kidney (Renal) Fibrosis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Kidney (Renal) Fibrosis Market Size and Volume Forecast by Application
13.4.1. Research Center
13.4.2. Hospital
13.4.3. Clinic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Kidney (Renal) Fibrosis Market Size and Volume Forecast by Type
13.7.1. Angiotensin Converting enzyme (ACE) Inhibitors
13.7.2. Pirfenidone
13.7.3. Renin Inhibitors
13.7.4. Angiotensin II Receptor Blockers (ARBs)
13.7.5. Vasopeptidase Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Kidney (Renal) Fibrosis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Kidney (Renal) Fibrosis Market: Market Share Analysis
14.2. Kidney (Renal) Fibrosis Distributors and Customers
14.3. Kidney (Renal) Fibrosis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. InterMune
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Galectin Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. La Jolla Pharmaceutical Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. ProMetic Life-Sciences Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. BioLine Rx Ltd
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Genzyme Corporation
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
